Structural Biology and the Design of New Therapeutics: From HIV and Cancer to Mycobacterial Infections: A Paper Dedicated to John Kendrew

Journal of Molecular Biology

Volumn 429, Issue 17, 2017, Pages 2677-2693

  Thomas, Sherine E ^a   Mendes, Vitor ^a   Kim, So Yeon ^a   Malhotra, Sony ^a   Ochoa Montaño, Bernardo ^a   Blaszczyk, Michal ^a   Blundell, Tom L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cancer; drug design discovery; fragment based; infectious disease; structure guided

Indexed keywords

BACTERIAL ENZYME; CYTOCHROME P450; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; MYCOBACTERIUM TUBERCULOSIS THYMIDYLATE KINASE; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; PROTEIN;

BACTERIAL GENOME; BACTERIAL INFECTION; CRYSTALLOGRAPHY; DRUG DEVELOPMENT; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALIGNANT NEOPLASM; MYCOBACTERIACEAE; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; REVIEW; CHEMISTRY; HISTORY; PROCEDURES; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; PROTEINS;

EID: 85022063278     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2017.06.014     Document Type: Review

References (109)

1. Perutz, R.R., Liquori, A.M., Eirich, F., X-ray and solubility studies of the haemoglobin of sickle-cell anaemia patients. Nature 167 (1951), 929–931.
2. Perutz, M.F., Rossmann, M.G., Cullis, A.F., Muirhead, H., Will, G., North, A.C., Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A resolution, obtained by X-ray analysis. Nature 185 (1960), 416–422.
3. Kendrew, J.C., Dickerson, R.E., Strandberg, B.E., Hart, R.G., Davies, D.R., Phillips, D.C., et al. Structure of myoglobin: a three-dimensional Fourier synthesis at 2 A resolution. Nature 185 (1960), 422–427.
4. Schlichtkrull, J.E.M., Insulin Crystals: Chemical & Biological Studies on Insulin Crystals & Insulin Zinc Suspensions. 1958, Ejnar Munksggard, Copenhagen.
5. Adams, M.J., Blundell, T.L., Dodson, E.J., Dodson, G.G., Vijayan, M., Baker, E.N., et al. Structure of rhombohedral 2 zinc insulin crystals. Nature 224 (1969), 491–495.
6. Blundell, T.L., Cutfield, J.F., Cutfield, S.M., Dodson, E.J., Dodson, G.G., Hodgkin, D.C., et al. Atomic positions in rhombohedral 2-zinc insulin crystals. Nature 231 (1971), 506–511.
7. Sanger, F., Sequences, sequences, and sequences. Annu. Rev. Biochem. 57 (1988), 1–28.
8. Beddell, C.R., Goodford, P.J., Norrington, F.E., Wilkinson, S., Wootton, R., Compounds designed to fit a site of known structure in human haemoglobin. Br. J. Pharmacol. 57 (1976), 201–209.
9. Skeggs, L.T., Dorer, F.E., Levine, M., Lentz, K.E., Kahn, J.R., Johnson, J.A., Anderson, R.R., (eds.) The Renin-Angiotensin System, 1980, Plenum, New York, 1–27.
10. Atkinson, A.B., et al. The Therapeutics of Hypertension. 1980, Academic and The Royal Society of Medicine, London, 29–61.
11. James, M.N., Hsu, I.N., Delbaere, L.T., Mechanism of acid protease catalysis based on the crystal structure of penicillopepsin. Nature 267 (1977), 808–813.
12. Subramanian, E., Swan, I.D., Liu, M., Davies, D.R., Jenkins, J.A., Tickle, I.J., et al. Homology among acid proteases: comparison of crystal structures at 3A resolution of acid proteases from Rhizopus chinensis and Endothia parasitica. Proc. Natl. Acad. Sci. U. S. A. 74 (1977), 556–559.
13. Tickle, I.J., Sibanda, B.L., Pearl, L.H., Hemmings, A.M., Blundell, T.L., Protein Crystallography, Interactive Computer Graphics & Drug Design X-ray Crystallography & Drug Design. 1984, Clarendon Press, Oxford, UK, 427–444.
14. Blundell, T., Sibanda, B.L., Pearl, L., Three-dimensional structure, specificity and catalytic mechanism of renin. Nature 304 (1983), 273–275.
15. Rahuel, J., Priestle, J.P., Grutter, M.G., The crystal structures of recombinant glycosylated human renin alone and in complex with a transition state analog inhibitor. J. Struct. Biol. 107 (1991), 227–236.
16. Dhanaraj, V., Dealwis, C.G., Frazao, C., Badasso, M., Sibanda, B.L., Tickle, I.J., et al. X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature 357 (1992), 466–472.
17. Tang, J., James, M.N., Hsu, I.N., Jenkins, J.A., Blundell, T.L., Structural evidence for gene duplication in the evolution of the acid proteases. Nature 271 (1978), 618–621.
18. Hiroyuki Toh, M.O., Saigo, Kaoru, Miyata, Takashi, Retroviral protease-like sequence in the yeast transposon Ty 1. Nature, 315, 1985, 691.
19. Pearl, L.H., Taylor, W.R., A structural model for the retroviral proteases. Nature 329 (1987), 351–354.
20. Jaskolski, M., Miller, M., Rao, J.K., Leis, J., Wlodawer, A., Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2-A resolution. Biochemistry 29 (1990), 5889–5898.
21. Jaskolski, M., Miller, M., Rao, M., Leis, J., Wlodawer, A., Structure of the aspartic protease from Rous sarcoma virus at 2A resolution. Krausslich, H., Oroszlan, S., Wimmer, E., (eds.) Current Communications in Molecular Biology, 1989, Cold Spring Harbor Press, Cold Spring Harbor, 235–243.
22. Navia, M.A., Fitzgerald, P.M., McKeever, B.M., Leu, C.T., Heimbach, J.C., Herber, W.K., et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337 (1989), 615–620.
23. Blundell, T., Pearl, L., Retroviral proteinases. A second front against AIDS. Nature 337 (1989), 596–597.
24. Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B.K., Baldwin, E., Weber, I.T., et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245 (1989), 616–621.
25. Lapatto, R., Blundell, T., Hemmings, A., Overington, J., Wilderspin, A., Wood, S., et al. X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes. Nature 342 (1989), 299–302.
26. Jaskolski, M., Dauter, Z., Wlodawer, A., A brief history of macromolecular crystallography, illustrated by a family tree and its Nobel fruits. FEBS J. 281 (2014), 3985–4009.
27. Bohacek, R.S., McMartin, C., Guida, W.C., The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16 (1996), 3–50.
28. Murray, C.W., Erlanson, D.A., Hopkins, A.L., Keseru, G.M., Leeson, P.D., Rees, D.C., et al. Validity of ligand efficiency metrics. ACS Med. Chem. Lett. 5 (2014), 616–618.
29. Harner, M.J., Frank, A.O., Fesik, S.W., Fragment-based drug discovery using NMR spectroscopy. J. Biomol. NMR 56 (2013), 65–75.
30. Murray, C.W., Verdonk, M.L., Rees, D.C., Experiences in fragment-based drug discovery. Trends Pharmacol. Sci. 33 (2012), 224–232.
31. Blundell, T.L., Jhoti, H., Abell, C., High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1 (2002), 45–54.
32. Scott, D.E., Coyne, A.G., Hudson, S.A., Abell, C., Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51 (2012), 4990–5003.
33. Niesen, F.H., Berglund, H., Vedadi, M., The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2 (2007), 2212–2221.
34. Navratilova, I., Hopkins, A.L., Fragment screening by surface plasmon resonance. ACS Med. Chem. Lett. 1 (2010), 44–48.
35. Taylor, R.D., MacCoss, M., Lawson, A.D., Combining molecular scaffolds from FDA-approved drugs: application to drug discovery. J. Med. Chem. 60 (2017), 1638–1647.
36. Abagyan, R., Totrov, M., High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 5 (2001), 375–382.
37. Hubbard, R.E., Murray, J.B., Experiences in fragment-based lead discovery. Methods Enzymol. 493 (2011), 509–531.
38. Winter, A., Sigurdardottir, A.G., DiCara, D., Valenti, G., Blundell, T.L., Gherardi, E., Developing antagonists for the Met-HGF/SF protein–protein interaction using a fragment-based approach. Mol. Cancer Ther. 15 (2016), 3–14.
39. World Health Organization, Global tuberculosis report. 2016.
40. Wallis, R.S., Maeurer, M., Mwaba, P., Chakaya, J., Rustomjee, R., Migliori, G.B., et al. Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect. Dis. 16 (2016), e34–e46.
41. Marras, T.K., Mendelson, D., Marchand-Austin, A., May, K., Jamieson, F.B., Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg. Infect. Dis. 19 (2013), 1889–1891.
42. Lai, C.C., Tan, C.K., Chou, C.H., Hsu, H.L., Liao, C.H., Huang, Y.T., et al. Increasing incidence of nontuberculous mycobacteria, Taiwan, 2000-2008. Emerg. Infect. Dis. 16 (2010), 294–296.
43. Qvist, T., Pressler, T., Hoiby, N., Katzenstein, T.L., Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir. Res., 15, 2014, 41.
44. Bryant, J.M., Grogono, D.M., Greaves, D., Foweraker, J., Roddick, I., Inns, T., et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 381 (2013), 1551–1560.
45. Nessar, R., Cambau, E., Reyrat, J.M., Murray, A., Gicquel, B., Mycobacterium abscessus: a new antibiotic nightmare. J. Antimicrob. Chemother. 67 (2012), 810–818.
46. Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., Catanzaro, A., Daley, C., Gordin, F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175 (2007), 367–416.
47. Lee, M.R., Sheng, W.H., Hung, C.C., Yu, C.J., Lee, L.N., Hsueh, P.R., Mycobacterium abscessus complex infections in humans. Emerg. Infect. Dis. 21 (2015), 1638–1646.
48. Parkins, M.D., Floto, R.A., Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. J. Cyst. Fibros. 14 (2015), 293–304.
49. Bar-On, O., Mussaffi, H., Mei-Zahav, M., Prais, D., Steuer, G., Stafler, P., et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J. Cyst. Fibros. 14 (2015), 53–62.
50. Heydari, H., Wee, W.Y., Lokanathan, N., Hari, R., Mohamed Yusoff, A., Beh, C.Y., et al. MabsBase: a Mycobacterium abscessus genome and annotation database. PLoS One, 8, 2013, e62443.
51. Benwill, J.L., Wallace, R.J. Jr., Mycobacterium abscessus: challenges in diagnosis and treatment. Curr. Opin. Infect. Dis. 27 (2014), 506–510.
52. Jarlier, V., Nikaido, H., Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J. Bacteriol. 172 (1990), 1418–1423.
53. Nguyen, L., Thompson, C.J., Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol. 14 (2006), 304–312.
54. Ripoll, F., Pasek, S., Schenowitz, C., Dossat, C., Barbe, V., Rottman, M., et al. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One, 4, 2009, e5660.
55. Kothavade, R.J., Dhurat, R.S., Mishra, S.N., Kothavade, U.R., Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria. Eur. J. Clin. Microbiol. Infect. Dis. 32 (2013), 161–188.
56. Ramakrishnan, G., Ochoa-Montano, B., Raghavender, U.S., Mudgal, R., Joshi, A.G., Chandra, N.R., et al. Enriching the annotation of Mycobacterium tuberculosis H37Rv proteome using remote homology detection approaches: insights into structure and function. Tuberculosis (Edinb.) 95 (2015), 14–25.
57. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., et al. The Protein Data Bank. Nucleic Acids Res. 28 (2000), 235–242.
58. Malhotra, S., Thomas, S.E., Ochoa Montano, B., Blundell, T.L., Structure-guided, target-based drug discovery—exploiting genome information from HIV to mycobacterial infections. Postepy Biochem. 62 (2016), 262–272.
59. Geerlof, A., Lewendon, A., Shaw, W.V., Purification and characterization of phosphopantetheine adenylyltransferase from Escherichia coli. J. Biol. Chem. 274 (1999), 27,105–27,111.
60. Abiko, Y., Investigations on pantothenic acid and its related compounds. IX. Biochemical studies. 4. Separation and substrate specificity of pantothenate kinase and phosphopantothenoylcysteine synthetase. J. Biochem. 61 (1967), 290–299.
61. Robishaw, J.D., Neely, J.R., Coenzyme A metabolism. Am. J. Phys. 248 (1985), E1–E9.
62. Izard, T., Geerlof, A., The crystal structure of a novel bacterial adenylyltransferase reveals half of sites reactivity. EMBO J. 18 (1999), 2021–2030.
63. Jackowski, S., Rock, C.O., Metabolism of 4′-phosphopantetheine in Escherichia coli. J. Bacteriol. 158 (1984), 115–120.
64. Gerdes, S.Y., Scholle, M.D., D'Souza, M., Bernal, A., Baev, M.V., Farrell, M., et al. From genetic footprinting to antimicrobial drug targets: examples in cofactor biosynthetic pathways. J. Bacteriol. 184 (2002), 4555–4572.
65. Wubben, T., Mesecar, A.D., Structure of Mycobacterium tuberculosis phosphopantetheine adenylyltransferase in complex with the feedback inhibitor CoA reveals only one active-site conformation. Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun. 67 (2011), 541–545.
66. Aghajanian, S., Worrall, D.M., Identification and characterization of the gene encoding the human phosphopantetheine adenylyltransferase and dephospho-CoA kinase bifunctional enzyme (CoA synthase). Biochem. J. 365 (2002), 13–18.
67. Daugherty, M., Polanuyer, B., Farrell, M., Scholle, M., Lykidis, A., de Crecy-Lagard, V., et al. Complete reconstitution of the human coenzyme A biosynthetic pathway via comparative genomics. J. Biol. Chem. 277 (2002), 21,431–21,439.
68. Zhyvoloup, A., Nemazanyy, I., Babich, A., Panasyuk, G., Pobigailo, N., Vudmaska, M., et al. Molecular cloning of CoA synthase. The missing link in CoA biosynthesis. J. Biol. Chem. 277 (2002), 22,107–22,110.
69. Zhao, L., Allanson, N.M., Thomson, S.P., Maclean, J.K., Barker, J.J., Primrose, W.U., et al. Inhibitors of phosphopantetheine adenylyltransferase. Eur. J. Med. Chem. 38 (2003), 345–349.
70. Miller, J.R., Thanabal, V., Melnick, M.M., Lall, M., Donovan, C., Sarver, R.W., et al. The use of biochemical and biophysical tools for triage of high-throughput screening hits—a case study with Escherichia coli phosphopantetheine adenylyltransferase. Chem. Biol. Drug Des. 75 (2010), 444–454.
71. de Jonge, B.L., Walkup, G.K., Lahiri, S.D., Huynh, H., Neckermann, G., Utley, L., et al. Discovery of inhibitors of 4′-phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy. Antimicrob. Agents Chemother. 57 (2013), 6005–6015.
72. Izard, T., The crystal structures of phosphopantetheine adenylyltransferase with bound substrates reveal the enzyme's catalytic mechanism. J. Mol. Biol. 315 (2002), 487–495.
73. Takahashi, H., Inagaki, E., Fujimoto, Y., Kuroishi, C., Nodake, Y., Nakamura, Y., et al. Structure and implications for the thermal stability of phosphopantetheine adenylyltransferase from Thermus thermophilus. Acta Crystallogr. D Biol. Crystallogr. 60 (2004), 97–104.
74. Badger, J., Sauder, J.M., Adams, J.M., Antonysamy, S., Bain, K., Bergseid, M.G., et al. Structural analysis of a set of proteins resulting from a bacterial genomics project. Proteins 60 (2005), 787–796.
75. Yoon, H.J., Kang, J.Y., Mikami, B., Lee, H.H., Suh, S.W., Crystal structure of phosphopantetheine adenylyltransferase from Enterococcus faecalis in the ligand-unbound state and in complex with ATP and pantetheine. Mol. Cells 32 (2011), 431–435.
76. Edwards, T.E., Leibly, D.J., Bhandari, J., Statnekov, J.B., Phan, I., Dieterich, S.H., et al. Structures of phosphopantetheine adenylyltransferase from Burkholderia pseudomallei. Acta Crystallogr. Sect. F: Struct. Biol. Cryst. Commun. 67 (2011), 1032–1037.
77. Chatterjee, R., Mondal, A., Basu, A., Datta, S., Transition of phosphopantetheine adenylyltransferase from catalytic to allosteric state is characterized by ternary complex formation in Pseudomonas aeruginosa. Biochim. Biophys. Acta 2016 (1864), 773–786.
78. Eventoff, W., Rossmann, M.G., The evolution of dehydrogenases and kinases. CRC Crit. Rev. Biochem. 3 (1975), 111–140.
79. Timofeev, V., Smirnova, E., Chupova, L., Esipov, R., Kuranova, I., X-ray study of the conformational changes in the molecule of phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis during the catalyzed reaction. Acta Crystallogr. D Biol. Crystallogr. 68 (2012), 1660–1670.
80. Wubben, T.J., Mesecar, A.D., Kinetic, thermodynamic, and structural insight into the mechanism of phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis. J. Mol. Biol. 404 (2010), 202–219.
81. Radoux, C.J., Olsson, T.S., Pitt, W.R., Groom, C.R., Blundell, T.L., Identifying interactions that determine fragment binding at protein hotspots. J. Med. Chem. 59 (2016), 4314–4325.
82. Hajduk, P.J., Huth, J.R., Fesik, S.W., Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48 (2005), 2518–2525.
83. Hajduk, P.J., Huth, J.R., Tse, C., Predicting protein druggability. Drug Discov. Today 10 (2005), 1675–1682.
84. Ichihara, O., Shimada, Y., Yoshidome, D., The importance of hydration thermodynamics in fragment-to-lead optimization. ChemMedChem 9 (2014), 2708–2717.
85. Gopal, P., Dick, T., Reactive dirty fragments: implications for tuberculosis drug discovery. Curr. Opin. Microbiol. 21 (2014), 7–12.
86. Barry, C.E. III, Boshoff, H.I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7 (2009), 845–855.
87. East, S.P., Silver, L.L., Multitarget ligands in antibacterial research: progress and opportunities. Expert Opin. Drug Discovery 8 (2013), 143–156.
88. Moreira, W., Lim, J.J., Yeo, S.Y., Ramanujulu, P.M., Dymock, B.W., Dick, T., Fragment-based whole cell screen delivers hits against M. tuberculosis and non-tuberculous mycobacteria. Front. Microbiol., 7, 2016, 1392.
89. Nikiforov, P.O., Blaszczyk, M., Surade, S., Boshoff, H.I., Sajid, A., Delorme, V., et al. Fragment-sized EthR inhibitors exhibit exceptionally strong ethionamide boosting effect in whole cell Mycobacterium tuberculosis assays. ACS Chem. Biol. 12 (2017), 1390–1396.
90. Nikiforov, P.O., Surade, S., Blaszczyk, M., Delorme, V., Brodin, P., Baulard, A.R., et al. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. Org. Biomol. Chem. 14 (2016), 2318–2326.
91. Hudson, S.A., McLean, K.J., Surade, S., Yang, Y.Q., Leys, D., Ciulli, A., et al. Application of fragment screening and merging to the discovery of inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121. Angew. Chem. Int. Ed. Eng. 51 (2012), 9311–9316.
92. Cole, S.T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998), 537–544.
93. Belin, P., Le Du, M.H., Fielding, A., Lequin, O., Jacquet, M., Charbonnier, J.B., et al. Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 7426–7431.
94. McLean, K.J., Carroll, P., Lewis, D.G., Dunford, A.J., Seward, H.E., Neeli, R., et al. Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv. J. Biol. Chem. 283 (2008), 33,406–33,416.
95. Hudson, S.A., McLean, K.J., Munro, A.W., Abell, C., Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets. Biochem. Soc. Trans. 40 (2012), 573–579.
96. Hudson, S.A., Surade, S., Coyne, A.G., McLean, K.J., Leys, D., Munro, A.W., et al. Overcoming the limitations of fragment merging: rescuing a strained merged fragment series targeting Mycobacterium tuberculosis CYP121. ChemMedChem 8 (2013), 1451–1456.
97. Kavanagh, M.E., Coyne, A.G., McLean, K.J., James, G.G., Levy, C.W., Marino, L.B., et al. Fragment-based approaches to the development of Mycobacterium tuberculosis CYP121 inhibitors. J. Med. Chem. 59 (2016), 3272–3302.
98. Noguchi, Y., Yasuda, Y., Tashiro, M., Kataoka, T., Kitamura, Y., Kandeel, M., et al. Synthesis of carbocyclic pyrimidine nucleosides and their inhibitory activities against Plasmodium falciparum thymidylate kinase. Parasitol. Int. 62 (2013), 368–371.
99. Martinez-Botella, G., Breen, J.N., Duffy, J.E., Dumas, J., Geng, B., Gowers, I.K., et al. Discovery of selective and potent inhibitors of gram-positive bacterial thymidylate kinase (TMK). J. Med. Chem. 55 (2012), 10,010–10,021.
100. Van Calenbergh, S., Pochet, S., Munier-Lehmann, H., Drug design and identification of potent leads against Mycobacterium tuberculosis thymidine monophosphate kinase. Curr. Top. Med. Chem. 12 (2012), 694–705.
101. Guimaraes, A.P., de Souza, F.R., Oliveira, A.A., Goncalves, A.S., de Alencastro, R.B., Ramalho, T.C., et al. Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox. Eur. J. Med. Chem. 91 (2015), 72–90.
102. Naik, M., Raichurkar, A., Bandodkar, B.S., Varun, B.V., Bhat, S., Kalkhambkar, R., et al. Structure guided lead generation for M. tuberculosis thymidylate kinase (Mtb TMK): discovery of 3-cyanopyridone and 1,6-naphthyridin-2-one as potent inhibitors. J. Med. Chem. 58 (2015), 753–766.
103. Henderson, R., Overview and future of single particle electron cryomicroscopy. Arch. Biochem. Biophys. 581 (2015), 19–24.
104. Scheres, S.H., RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180 (2012), 519–530.
105. Brown, A., Amunts, A., Bai, X.C., Sugimoto, Y., Edwards, P.C., Murshudov, G., et al. Structure of the large ribosomal subunit from human mitochondria. Science 346 (2014), 718–722.
106. Wong, W., Bai, X.C., Brown, A., Fernandez, I.S., Hanssen, E., Condron, M., et al. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine. elife, 3, 2014, e03080, 10.7554/eLife.03080.
107. Jubb, H.C., Higueruelo, A.P., Ochoa-Montano, B., Pitt, W.R., Ascher, D.B., Blundell, T.L., Arpeggio: a web server for calculating and visualising interatomic interactions in protein structures. J. Mol. Biol. 429 (2017), 365–371.
108. Pearce, N.M., Krojer, T., Bradley, A.R., Collins, P., Nowak, R.P., Talon, R., et al. A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density. Nat. Commun., 8, 2017, 15,123.
109. Koul, A., Arnoult, E., Lounis, N., Guillemont, J., Andries, K., The challenge of new drug discovery for tuberculosis. Nature 469 (2011), 483–490.